A CLINICAL OVERVIEW OF DYSLIPIDEMIAS - TREATMENT STRATEGIES

The strong epidemiologic relationship) between specific lipoprotein levels (such as elevated low-density lipoprotein cholesterol or decreased high-density lipoprotein cholesterol) and the future development of coronary heart disease has been well documented. Within the past several years, landmark clinical trials have clearly demonstrated that the incidence of coronary heart disease events is reduced when lipoprotein abnormalities are corrected via pharmacologic therapy. These findings have prompted clinicians to become more vigilant with regard to recognition of dyslipidemias and institution of treatment. This review focuses on the more common primary and secondary dyslipidemias and the currently available lipid-lowering therapies for each disorder. Results of recent coronary angiographic trials are discussed, and implications for the medical management of established coronary heart disease are assessed.